Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine J Mummery

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2024
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Nature Medicine|October 16, 2023
Author Correction: Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 15, 2026
Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS)Philippe Amouyel, Sandrine Andrieu, Angela Bradshaw, et al.
Nature Medicine|April 24, 2023
Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
Frontiers in Aging Neuroscience|July 5, 2022
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention TrialsAndrew J Aschenbrenner, Jason Hassenstab, Guoqiao Wang, et al.
Brain : a Journal of Neurology|March 24, 2017
Clinical and genetic characterization of leukoencephalopathies in adultsDavid S Lynch, Anderson Rodrigues Brandão de Paiva, Wei Jia Zhang, et al.
JAMA Network Open|September 24, 2021
Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical TrialPeter A Ljubenkov, Lauren Edwards, Leonardo Iaccarino, et al.
Eclinicalmedicine|August 17, 2021
Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional studyLaura A Benjamin, Ross W Paterson, Rachel Moll, et al.
Brain Communications|January 17, 2024
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injuryMaxime Taquet, Zuzanna Skorniewska, Henrik Zetterberg, et al.
The Lancet. Neurology|July 24, 2021
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional studyAnne M Fagan, Rachel L Henson, Yan Li, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2024
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Nature Medicine|October 16, 2023
Author Correction: Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 15, 2026
Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS)Philippe Amouyel, Sandrine Andrieu, Angela Bradshaw, et al.
Nature Medicine|April 24, 2023
Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
Frontiers in Aging Neuroscience|July 5, 2022
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention TrialsAndrew J Aschenbrenner, Jason Hassenstab, Guoqiao Wang, et al.
Brain : a Journal of Neurology|March 24, 2017
Clinical and genetic characterization of leukoencephalopathies in adultsDavid S Lynch, Anderson Rodrigues Brandão de Paiva, Wei Jia Zhang, et al.
JAMA Network Open|September 24, 2021
Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical TrialPeter A Ljubenkov, Lauren Edwards, Leonardo Iaccarino, et al.
Eclinicalmedicine|August 17, 2021
Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional studyLaura A Benjamin, Ross W Paterson, Rachel Moll, et al.
Brain Communications|January 17, 2024
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injuryMaxime Taquet, Zuzanna Skorniewska, Henrik Zetterberg, et al.
The Lancet. Neurology|July 24, 2021
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional studyAnne M Fagan, Rachel L Henson, Yan Li, et al.
Pageof 8